{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:31:18Z","timestamp":1780734678772,"version":"3.54.1"},"reference-count":53,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PRM"],"published-print":{"date-parts":[[2020,11,23]]},"abstract":"<jats:p>COVID-19, the respiratory and frequently systemic disease caused by the novel SARS-COV-2 virus, was first recognized in December 2019 and quickly spread to become a pandemic and world-wide public health emergency over the subsequent 3\u20134\u00a0months. While COVID-19 has a very low morbidity rate across approximately 80% of the population, it has a high morbidity and mortality rate in the remaining 20% of the population.1 These numbers have put a significant strain on medical systems around the world. Patients with neuromuscular diseases such as those with Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), tend to be more medically fragile and have higher health care needs than the general population. Respiratory insufficiency, cardiac disease, obesity, and immunocompromised status due to chronic steroid treatments in certain patient populations with neuromuscular conditions are specific risk factors for severe COVID-19 disease. In general, the pediatric population has shown to be less severely impacted with lower infection rates and lower morbidity and mortality rates than the adult population, however, as expected, children with underlying medical conditions are at higher risk of morbidity from COVID-19 than their peers.2 Many patients with neuromuscular disease also rely heavily on caregiver support through their lifetime and thus maintaining the health of their primary caregivers is also a significant consideration in the health and well-being of the patients. This paper will address routine and emergency medical care, rehabilitation services, and other considerations for the pediatric patient with a neuromuscular condition during the COVID-19 pandemic.<\/jats:p>","DOI":"10.3233\/prm-200768","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T10:24:52Z","timestamp":1605263092000},"page":"405-414","source":"Crossref","is-referenced-by-count":9,"title":["Pediatric neuromuscular disorders: Care considerations during the COVID-19 pandemic"],"prefix":"10.1177","volume":"13","author":[{"given":"Anne Troike","family":"Stratton","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Ogden","family":"Roberts III","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Diabetes and Endocrinology, Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Pulmonary Medicine, Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Carry","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Parsons","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Neurology, Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders, Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Apkon","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Fischahs Chair in Pediatric Rehabilitation, Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"13","key":"10.3233\/PRM-200768_ref1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA."},{"issue":"5","key":"10.3233\/PRM-200768_ref2","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/risa.13500","article-title":"Consideration of the Aerosol Transmission for COVID-19 and Public Health","volume":"40","author":"Anderson","year":"2020","journal-title":"Risk Anal."},{"key":"10.3233\/PRM-200768_ref3","doi-asserted-by":"crossref","unstructured":"Yu X, Yang R. COVID-19 transmission through asymptomatic carriers is a challenge to containment [published online ahead of print, 2020 Apr 4]. Influenza Other Respir Viruses. 2020; doi: doi10.1111\/irv.12743,","DOI":"10.1111\/irv.12743"},{"key":"10.3233\/PRM-200768_ref4","doi-asserted-by":"publisher","first-page":"104773","DOI":"10.1016\/j.ssci.2020.104773","article-title":"Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic [published online ahead of print, 2020 Apr 15]","volume":"128","author":"Bruinen de Bruin","year":"2020","journal-title":"Saf Sci."},{"issue":"10239","key":"10.3233\/PRM-200768_ref5","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(20)31129-6","article-title":"Kawasaki-like disease: emerging complication during the COVID-19 pandemic","volume":"395","author":"Viner","year":"2020","journal-title":"Lancet."},{"key":"10.3233\/PRM-200768_ref7","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26902"},{"issue":"20","key":"10.3233\/PRM-200768_ref8","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA."},{"issue":"10239","key":"10.3233\/PRM-200768_ref9","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study","volume":"395","author":"Cummings","year":"2020","journal-title":"Lancet."},{"key":"10.3233\/PRM-200768_ref10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"issue":"6","key":"10.3233\/PRM-200768_ref11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2213-2600(20)30228-9","article-title":"Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities","volume":"8","author":"Kirby","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.3233\/PRM-200768_ref12","doi-asserted-by":"crossref","unstructured":"Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 \u2013 COVID-NET, 14 States, March 1-20, 2020. Morb Mortal Wkly Rep. 2020; 69: 458-464.","DOI":"10.15585\/mmwr.mm6915e3"},{"issue":"4","key":"10.3233\/PRM-200768_ref13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.3233\/PRM-200768_ref14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord."},{"issue":"6","key":"10.3233\/PRM-200768_ref15","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1378\/chest.110.6.1566","article-title":"Criteria for extubation and tracheostomy tube removal for patients with ventilatory failure. A different approach to weaning","volume":"110","author":"Bach","year":"1996","journal-title":"Chest."},{"key":"10.3233\/PRM-200768_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.06.026"},{"issue":"3","key":"10.3233\/PRM-200768_ref17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MOP.0000000000000498","article-title":"Respiratory complications, management and treatments for neuromuscular disease in children","volume":"29","author":"Buu","year":"2017","journal-title":"Curr Opin Pediatr."},{"key":"10.3233\/PRM-200768_ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0883073810381924"},{"issue":"3","key":"10.3233\/PRM-200768_ref19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/0883073812436605","article-title":"Consensus statement on standard of care for congenital myopathies","volume":"27","author":"Wang","year":"2012","journal-title":"J Child Neurol."},{"issue":"5","key":"10.3233\/PRM-200768_ref20","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1378\/chest.118.5.1390","article-title":"Prevention of pulmonary morbidity for patients with neuromuscular disease","volume":"118","author":"Tzeng","year":"2000","journal-title":"Chest."},{"issue":"4","key":"10.3233\/PRM-200768_ref21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4187\/respcare.03584","article-title":"Efficacy of mechanical insufflation-exsufflation in extubating unweanable subjects with restrictive pulmonary disorders","volume":"60","author":"Bach","year":"2015","journal-title":"Respir Care."},{"issue":"6","key":"10.3233\/PRM-200768_ref22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1248\/bpb.b12-01076","article-title":"In vitro evaluation of the ciliary beat frequency of the rat nasal epithelium using a high-speed digital imaging system","volume":"36","author":"Inoue","year":"2013","journal-title":"Biol Pharm Bull."},{"issue":"3","key":"10.3233\/PRM-200768_ref23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/00005537-200203000-00029","article-title":"Nasal mucociliary transport: new evidence for a key role of ciliary beat frequency","volume":"112","author":"Boek","year":"2002","journal-title":"Laryngoscope."},{"issue":"7","key":"10.3233\/PRM-200768_ref24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0883073809350223","article-title":"Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial","volume":"25","author":"Yuan","year":"2010","journal-title":"J Child Neurol."},{"issue":"6","key":"10.3233\/PRM-200768_ref25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1513\/AnnalsATS.201509-597OC","article-title":"The Impact of high-frequency chest wall oscillation on healthcare use in patients with neuromuscular diseases","volume":"13","author":"Lechtzin","year":"2016","journal-title":"Ann Am Thorac Soc."},{"issue":"10","key":"10.3233\/PRM-200768_ref26","first-page":"940","article-title":"Effect of intrapulmonary percussive ventilation on mucus clearance in Duchenne muscular dystrophy patients: a preliminary report","volume":"48","author":"Toussaint","year":"2003","journal-title":"Respir Care."},{"issue":"6","key":"10.3233\/PRM-200768_ref27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/archpedi.159.6.526","article-title":"Intrapulmonary percussive ventilation vs incentive spirometry for children with neuromuscular disease","volume":"159","author":"Reardon","year":"2005","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"20","key":"10.3233\/PRM-200768_ref28","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology."},{"issue":"3","key":"10.3233\/PRM-200768_ref29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.3233\/PRM-200768_ref30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1371\/currents.md.d18deef7dac96ed135e0dc8739917b6e","article-title":"The PJ Nicholoff Steroid Protocol for Duchenne and Becker Muscular Dystrophy and Adrenal Suppression","author":"Kinnett","year":"2017","journal-title":"PLoS Curr."},{"issue":"1","key":"10.3233\/PRM-200768_ref31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mus.20075","article-title":"Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data","volume":"30","author":"Bromberg","year":"2004","journal-title":"Muscle Nerve."},{"key":"10.3233\/PRM-200768_ref32","doi-asserted-by":"publisher","first-page":"1739831","DOI":"10.1155\/2018\/1739831","article-title":"Pediatric Adrenal Insufficiency: Diagnosis, Management, and New Therapies","volume":"2018","author":"Bowden","year":"2018","journal-title":"Int J Pediatr."},{"issue":"5","key":"10.3233\/PRM-200768_ref33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1530\/EJE-15-0608","article-title":"Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol","volume":"173","author":"Woods","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"10.3233\/PRM-200768_ref34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/JND-180346","article-title":"Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations","volume":"6","author":"Bowden","year":"2019","journal-title":"J Neuromuscul Dis."},{"issue":"5","key":"10.3233\/PRM-200768_ref35","doi-asserted-by":"publisher","first-page":"dgaa148","DOI":"10.1210\/clinem\/dgaa148","article-title":"Our Response to COVID-19 as Endocrinologists and Diabetologists","volume":"105","author":"Kaiser","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"10239","key":"10.3233\/PRM-200768_ref36","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/S0140-6736(20)30749-2","article-title":"Caution against corticosteroid-based COVID-19 treatment","volume":"395","author":"Tang","year":"2020","journal-title":"Lancet."},{"issue":"18","key":"10.3233\/PRM-200768_ref37","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"10.3233\/PRM-200768_ref38","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13311-018-00687-z","article-title":"Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy","volume":"15","author":"Shieh","year":"2018","journal-title":"Neurotherapeutics."},{"issue":"21","key":"10.3233\/PRM-200768_ref39","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology."},{"issue":"3","key":"10.3233\/PRM-200768_ref40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs."},{"issue":"18","key":"10.3233\/PRM-200768_ref41","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med."},{"key":"10.3233\/PRM-200768_ref42","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag."},{"issue":"11","key":"10.3233\/PRM-200768_ref43","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord."},{"issue":"2","key":"10.3233\/PRM-200768_ref44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord."},{"issue":"11","key":"10.3233\/PRM-200768_ref45","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/dmcn.12213","article-title":"Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy","volume":"55","author":"Mayhew","year":"2013","journal-title":"Dev Med Child Neurol."},{"issue":"6","key":"10.3233\/PRM-200768_ref46","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nmd.2011.02.014","article-title":"Assessing upper limb function in nonambulant SMA patients: development of a new module","volume":"21","author":"Mazzone","year":"2011","journal-title":"Neuromuscul Disord."},{"issue":"11","key":"10.3233\/PRM-200768_ref47","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/dmcn.12220","article-title":"Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy","volume":"55","author":"Mayhew","year":"2013","journal-title":"Dev Med Child Neurol."},{"issue":"3","key":"10.3233\/PRM-200768_ref48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord."},{"issue":"12","key":"10.3233\/PRM-200768_ref49","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J Child Neurol."},{"issue":"2","key":"10.3233\/PRM-200768_ref50","doi-asserted-by":"publisher","first-page":"e0172346","DOI":"10.1371\/journal.pone.0172346","article-title":"Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool","volume":"12","author":"Ramsey","year":"2017","journal-title":"PLoS One."},{"issue":"3","key":"10.3233\/PRM-200768_ref51","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.pmr.2012.06.009","article-title":"Prevention and management of limb contractures in neuromuscular diseases","volume":"23","author":"Skalsky","year":"2012","journal-title":"Phys Med Rehabil Clin N Am."},{"issue":"5","key":"10.3233\/PRM-200768_ref52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S2352-4642(20)30095-X","article-title":"School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review","volume":"4","author":"Viner","year":"2020","journal-title":"Lancet Child Adolesc Health."},{"issue":"6","key":"10.3233\/PRM-200768_ref53","doi-asserted-by":"publisher","first-page":"e1650","DOI":"10.1542\/peds.2015-3409","article-title":"The Individuals With Disabilities Education Act (IDEA) for Children With Special Educational Needs","volume":"136","author":"Lipkin","year":"2015","journal-title":"Pediatrics."},{"key":"10.3233\/PRM-200768_ref54","doi-asserted-by":"crossref","unstructured":"ArmitageR., NellumsLB., Considering inequalities in the school closure response to COVID-19, Lancet Glob Health. 2020; 8(5): e644. doi: 10.1016\/S2214-109X(20)30116-9.","DOI":"10.1016\/S2214-109X(20)30116-9"}],"container-title":["Journal of Pediatric Rehabilitation Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/PRM-200768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:37:14Z","timestamp":1777610234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/PRM-200768"}},"subtitle":[],"editor":[{"given":"Matthew","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Christian","family":"Vercler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":53,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/prm-200768","relation":{},"ISSN":["1875-8894","1874-5393"],"issn-type":[{"value":"1875-8894","type":"electronic"},{"value":"1874-5393","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,23]]}}}